Markus Mühlemann

OnconiX is a personalized oncology startup dedicated to transforming cancer treatment by enabling oncologists to rapidly select the right therapy for each patient. Today, doctors treating solid tumors face significant uncertainty, often relying on trial-and-error prescribing that leads to ineffective treatments, unnecessary side effects, increased healthcare costs, and lower patient quality of life. OnconiX directly addresses this critical gap by providing precise, personalized tumor drug-response predictions within days - giving oncologists the detailed decision-making support they urgently need to improve patient outcomes and reduce treatment-associated risks.